Stocktoria
Almirall, S.A. ALM.MC
Almirall, S.A. (ALM.MC) earns a Piotroski F-score of 8/9 (strong financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 1.04% (safety: moderate). FY2025 revenue was €1.1B at a 4.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Healthcare · percentile among 79 companies
Percentile vs other Healthcare companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 8/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.155 |
| Retained earnings / assets | 0.02 |
| EBIT / assets | 0.029 |
| Equity / liabilities | 1.75 |
About Almirall, S.A.
Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism, anti-infective for systemic use, cardiovascular system, dermatological, genito urinary system and sex hormones, immunostimulants, metabolism, musculo-skeletal system, nervous system, respiratory system, systemic hormonal preparations. It also develops tirbanibulin for actinic keratosis, and tildrakizumab for psoriatic arthritis under the registration phase, as well as lebrikizumab for atopic dermatitis pediatric in phase 2; Anti-IL-1RAP mAb for hidradenitis suppurativa, anti-IL-1RAP mAb for inflammatory skin disease, Anti-IL-21 mAb for hidradenitis suppurativa, IL-2muFc for alopecia areata, IL-2muFc for atopic dermatitis, and IL-2muFc for inflammatory skin disease in phase 2; readthrough inducer for rare dermatology in phase 1; and anti-IL-13/OX40L BsAb for atopic dermatitis, SMOL oral for Th2-driven diseases, and mRNA/LNP for non-melanoma skin cancer in preclinical stage. It has research and development agreements with Evotec, Ichnos, Simcere, Etherna, Novo Nordisk, and Eloxx. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
FAQ
Is ALM.MC financially healthy?
Almirall, S.A.'s Piotroski F-score is 8/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does ALM.MC pay a dividend, and is it safe?
Yes. Almirall, S.A. pays a dividend yielding about 1.04% with a 56.8% payout ratio, rated “moderate” for safety.
How profitable is ALM.MC?
In FY2025, Almirall, S.A. had a net margin of 4.2% and a return on equity of 3.1%.
What is ALM.MC's P/E ratio?
Almirall, S.A.'s trailing price-to-earnings (P/E) ratio is about 54.6×, based on its latest annual earnings.
What is the analyst price target for ALM.MC?
The average Wall-Street price target for Almirall, S.A. is €14.57, about 25.9% above the recent price, from 12 analysts (consensus: buy).
Is ALM.MC a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Almirall, S.A.: a Piotroski F-score of 8/9, an Altman Z″ in the safe zone, a P/E of about 54.6×, a dividend yield of 1.04%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · ES · as of 2025-12-31. Figures in EUR. Facts plus Stocktoria's own computed scores — not investment advice.